PL EN


Preferences help
enabled [disable] Abstract
Number of results
2019 | 127 | 3 | 123-138
Article title

Betulin and its derivatives – precursors of new drugs

Content
Title variants
Languages of publication
EN
Abstracts
EN
White birch bark extract, used in traditional medicine, has many medical properties. Its main components are betulin and betulinic acid - lupane type pentacyclic triterpenes. The discovery of the anti-tumor and anti-viral properties of betulinic acid has become an impulse to modify the structures of these compounds in order to obtain better activity. Over twenty years of research, several derivatives have been selected that have significantly better anti-tumor or antiviral properties than their precursors. This paper presents all new derivatives of betulin and betulinic acid, which have been tested in phase I, II or III of clinical trials. Clinical experiments on animals with natural cancers have also been described. The results obtained by various research teams give hope for the potential use of these compounds in therapy. At the same time, the presented analysis shows that the implementation of the new drug on the market is a process that lasts 10-15 years, which, despite the involvement of huge financial and human resources, does not guarantee success.
Year
Volume
127
Issue
3
Pages
123-138
Physical description
Contributors
  • Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 6a Chalubinskiego Str., 50-368 Wroclaw, Poland
author
  • Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 6a Chalubinskiego Str., 50-368 Wroclaw, Poland
References
  • [1] Bielska E, Lucas X, Czerwoniec A, Kasprzak JM, Kamińska KH, Bujnicki JM. Virtul screening strategies in drug design – methods and applications. Journal of Biotechnology, Computational Biology and Bionanotechnology 2011; 92: 249-264
  • [2] Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J 2010; 12: 397-406
  • [3] Dinda B, Dednath S, Mohanta B, Harigaya Y. Naturally occurring triterpenoid saponins. Chem Biodivers 2010; 10: 2327-2580
  • [4] Sumner LW, Mendes P, Dixon RA. Plant metabolomics: large-scale phytochemistry in the functional genomics era. Phytochemistry. 2003; 62: 817-836
  • [5] Xu R, Fazio GC, Matsuda SPT. On the origins of triterpenoid skeletal diversity. Phytochemistry 2003; 65: 261-291
  • [6] Jäger S, Trojan H, Kopp T, Laszczyk MN, Scheffler A. Pentacyclic triterpene distribution in various plants - rich sources for a new group of multi-potent plant extracts. Molecules 2009; 4: 2016-2031
  • [7] Rastogi S, Pandey MM, Kumar Singh Rawat A. Medicinal plants of the genus Betula-traditional uses and photochemical-pharmacological review. J Ethnopharmacol 2015; 159: 62-83
  • [8] Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1: 1046-1051
  • [9] Krasutsky PA. Birch barkresearch and development. Nat Prod Rep 2006; 23: 919-942
  • [10] Alakurtti S, Mäkelä T, Koskimies S, Yli-Kauhaluoma J. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci. 2006; 29: 1-13
  • [11] Król SK, Kiełbus M, Rivero-Muller A, Stepulak A. Comprehensive review on betulin as a potent aticancer agent. BioMed Research International Volume 2015, Article ID 584189, 11 pages. http://dx.doi.org/10.1155/2015/584189
  • [12] Csuk R, Schuck K, Schafer R. A practical synthesis of betulinic acid. Tetrahed Lett 2006; 47: 8769-8770
  • [13] Scheffler A. Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract. European Patent Office. Patent No. EE 200200552(A) 2004.
  • [14] Sousa JLC, Freire CSR, Silvestre AJD, Silva AMS. Recent Developments in the Functionalization of Betulinic Acid and Its Natural Analogues: A Route to New Bioactive Compounds. Molecules 2019; 24: E355
  • [15] Drąg-Zalesińska M, Wysocka T, Borska S, Drąg M, Poręba M, Choromańska A, Kulbacka J, Saczko J. The new esters derivatives of betulin and betulinic acid in epidermoid squamous carcinoma treatment - In vitro studies. Biomed Pharmacother 2015; 72: 91-97.
  • [16] Salti GI, Kichina JV, Das Gupta TK, Uddin S, Bratescu L, Pezzuto JM, Mehta RG, Constantinou AI. Betulinic acid reduces ultraviolet -C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Res 2001; 11: 99-104
  • [17] Dillon LW, Pierce LC, Lehman CE, Nikiforov YE, Wang YH. DNA topoisomerases participate in fragility of the oncogene RET. PLoS One 2013; 11: e75741
  • [18] Ali-Seyed M, Jantan I, Vijayaraghavan K, Bukhari SN. Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy. Chem Biol Drug Des 2016; 87: 517-536
  • [19] Fulda S. Betulinic Acid for cancer treatment and prevention. Int J Mol Sci 2008; 9: 1096-1107
  • [20] Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009; 75: 1549-1560
  • [21] Tan Y, Yu R, Pezzuto JM. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 2003; 9: 2866-2875
  • [22] Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67: 2816-2823
  • [23] Drąg-Zalesińska M, Drąg M, Poręba M, Borska S, Kulbacka J, Saczko J. Anticancer properties of ester derivatives of betulin in human metastatic melanoma cells (Me-45). Cancer Cell Int 2017; 17: 4
  • [24] Csuk R. Betulinic acid and its derivatives: a patent review (2008-2013) Expert Opin Ther Pat 2014; 24: 913-923
  • [25] Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011; 3: 476-480
  • [26] Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest 2009; 39: 384-394
  • [27] Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R, Vordermark D. Characterization of NVX‐207, a novel betulinic acid‐derived anti‐cancer compound. Int J Mol Sci 2014; 30:19777-19790
  • [28] Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JM, Paschke R. In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and in vivo safety assessment of the compound NVX-207 in two horses. Chem Biol Interact 2016; 25: 20-29
  • [29] Gonzalez P, Mader I, Tchoghandjian A, Enzenmüller S, Cristofanon S, Basit F, Debatin KM, Fulda S. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 2012; 19: 1337-1346
  • [30] Fischer S, Ronellenfitsch MW, Thiepold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S, Bähr O. Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. PLoS One 2014; 17: e94921
  • [31] Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS, Lee KH. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994; 57: 243-247
  • [32] Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev 2007; 9: 162-172
  • [33] Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, Smith PC, Ballow C. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007; 51: 3063-3066
  • [34] Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE. Phase I and II study of the safety, virologic effect, and pharmacokinetics/ pharmacodynamics of single-dose 3-o-(3',3'- dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007; 51: 3574-3581
  • [35] Knapp DJ, Harrigan PR, Poon AF, Brumme ZL, Brockman M, Cheung PK. In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1. J Clin Microbiol. 2011; 49: 201-208
  • [36] Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F. A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob Agents Chemother 2011; 55: 3324-3329
  • [37] Regueiro-Ren A, Liu Z, Chen Y, Sin N, Sit SY, Swidorski JJ, Chen J, Venables BL, Zhu J, Nowicka-Sans B, Protack T, Lin Z, Terry B, Samanta H, Zhang S, Li Z, Beno BR, Huang XS, Rahematpura S, Parker DD, Haskell R, Jenkins S, Santone KS, Cockett MI, Krystal M, Meanwell NA, Hanumegowda U, Dicker IB. Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity. ACS Med Chem Lett 2016; 22: 568-572
  • [38] Morales-Ramirez J, Bogner JR, Molina JM, Lombaard J, Dicker IB, Stock DA, Degrosky M, Gartland M, Pene Dumitrescu T, Min S, Llamoso C, Joshi SR, Lataillade M. Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial. PLoS One 2018; 23: e0205368
  • [39] Johnson M, Jewell RC, Peppercorn A, Gould E, Xu J, Lou Y, Davies M, Baldwin S, Tenorio AR, Burke M, Jeffrey J, Johns BA. The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacol Res Perspect 2018; 6: e00408
  • [40] Jäger S, Laszczyk MN, Scheffler A. A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex). Molecules 2008; 13: 3224-3235
  • [41] Huyke C, Laszczyk M, Scheffler A, Ernst R, Schempp CM. Treatment of actinic keratoses with birch bark extract: a pilot study. J Dtsch Dermatol Ges 2006; 4: 132-136
  • [42] Huyke C, Reuter J, Rödig M, Kersten A, Laszczyk M, Scheffler A, Nashan D, Schempp C. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 2009; 7: 128-133
  • [43] Scheffler A. Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel. European Patent Office, Patent No. EP 1 758 555 B1, 2009
  • [44] Scheffler A. Use of an oleogel containing triterpene for healing wounds. United States Patent Aplication Publication 2012; Patent No. US 2012/0231054 A1
  • [45] Pflugfelder A, Andonov E, Weide B, Dirschka T, Schempp C, Stockfleth E, Stratigos A, Krüger-Krasagakis S, Bauer J, Garbe C, Eigentler TK. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. Br J Dermatol 2015; 172: 926-932
  • [46] Haque S, Nawrot DA, Alakurtti S, Ghemtio L, Yli-Kauhaluoma J, Tammela P. Screening and characterization of antimicrobial properties of semisynthetic betulin derivatives. Plos One 2014; 9: e102696
  • [47] Dharmappa KK, Kumar RV, Nataraju A, Mohamed R, Shivaprasad HV, Vishwanath BS. Anti-inflammatory activity of oleanolic acid by inhibition of secretory phospholipase A2. Planta Med 2009; 75: 211-215
  • [48] Barret JP, Podmelle F, Lipový B, Rennekampff HO, Schumann H, Schwieger-Briel A, Zahn TR, Metelmann HR; BSH-12 and BSG-12 study groups. Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program. Burns 2017; 43: 1284-1294
  • [49] Kindler S, Schuster M, Seebauer C, Rutkowski R, Hauschild A, Podmelle F, Metelmann C, Metelmann B, Müller-Debus C, Metelmann HR, Metelmann I. Triterpenes for Well-Balanced Scar Formation in Superficial Wounds. Molecules 2016; 21: E1129
  • [50] Lipový B, Fiamoli M, Mager R, Jelínková Z, Jarkovský J, Chaloupková Z, Holoubek J, Suchánek I, Brychta P: Oleogel-s10 to accelerate healing of donor sites: monocentric results of phase III clinical trial. Acta Chir Plast 2018; 59: 129-134
  • [51] Frew Q, Rennekampff HO, Dziewulski P, Moiemen N, Moiemen N. BBW-11 study group, Zahn T, Hartmann B: Betulin wound gel accelerated healing of superficial partial thickness burns: Results of a randomized, intra-individually controlled, phase III trial with 12-months follow-up. Burns 2018 Dec 14. pii: S0305-4179(18)30545-X. doi:10.1016/j.burns.2018.10.019
  • [52] Ebeling S, Naumann K, Pollok S, Wardecki T, Vidal-Y-Sy S, Nascimento JM, Boerries M, Schmidt G, Brandner JM, Merfort I. From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. PLoS One 2014; 22: e86147
  • [53] Woelfle U, Laszczyk MN, Kraus M, Leuner K, Kersten A, Simon-Haarhaus B, Scheffler A, Martin SF, Müller WE, Nashan D, Schempp CM. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol 2010; 130: 113-123.
  • [54] Schwieger-Briel A, Kiritsi D, Schempp C, Has C, Schumann H: Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study. Dermatol Res Pract 2017; 2017: 5068969
  • [55] Scheffler A. The Wound Healing Properties of Betulin from Birch Bark from Bench to Bedside. Planta Med 2019. doi: 10.1055/a-0850-0224
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-0338f690-415a-4950-8660-2a9de15be9c7
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.